ELTX (Elicio Therapeutics) Scaled Net Operating Assets: -0.08 (As of Mar. 2026)


ELTX Elicio Therapeutics Inc ELTX
32 GF Score
Price $3.99
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics Scaled Net Operating Assets?

Elicio Therapeutics ELTX +4.85% 32 Scaled Net Operating Assets is -0.08 as of Mar. 2026. GuruFocus rates ELTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Elicio Therapeutics's operating assets for the quarter that ended in Mar. 2026 was $7.74 Mil. Elicio Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was $9.79 Mil. Elicio Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $25.86 Mil. Therefore, Elicio Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.08.

Elicio Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics Scaled Net Operating Assets Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial -3.66 -6.81 0.24 -0.11 -0.09

Elicio Therapeutics Quarterly Data
Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 -0.19 -0.06 -0.09 -0.08

ELTX vs GOSS, GANX, ACET: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Elicio Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicio Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Elicio Therapeutics's Scaled Net Operating Assets falls into.


ELTX
32GF Score
Elicio Therapeutics Inc ELTX
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Elicio Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(7.299-9.714)/28.178
=-0.09

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=25.862 - 18.563
=7.299

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=24.226 - 13.501 - 1.011
=9.714

Elicio Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(7.741-9.786)/25.862
=-0.08

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=22.689 - 14.948
=7.741

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=24.126 - 13.298 - 1.042
=9.786

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.08 mean?
Elicio Therapeutics (ELTX) has a Scaled Net Operating Assets of -0.08 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Elicio Therapeutics and its competitors.
Is Elicio Therapeutics' Scaled Net Operating Assets too high?
Elicio Therapeutics' current Scaled Net Operating Assets is -0.08. Overall, Elicio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Scaled Net Operating Assets compare to GOSS and GANX?
Elicio Therapeutics' Scaled Net Operating Assets of -0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current Scaled Net Operating Assets is -0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Scaled Net Operating Assets of -0.08. The current Scaled Net Operating Assets is -0.08. Elicio Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Scaled Net Operating Assets is -0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
32GF Score

Get the complete analysis for ELTX

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.99
Price